Return-Path: <> Delivered-To: logoandw@mgh-web11.maghost.ro Received: from mgh-web11.maghost.ro by mgh-web11.maghost.ro with LMTP id ECsVLYfXmWnM1hoAJwI5NA (envelope-from <>) for ; Sat, 21 Feb 2026 18:04:23 +0200 Return-path: <> Envelope-to: webmaster@globalnetworking.net Delivery-date: Sat, 21 Feb 2026 18:04:23 +0200 Received: from [162.128.75.176] (port=39848 helo=chri.shop) by mgh-web11.maghost.ro with esmtp (Exim 4.98) id 1vtpT1-00000007NXk-33tt for webmaster@globalnetworking.net; Sat, 21 Feb 2026 18:04:23 +0200 Received: from [40.107.192.117] ([40.107.192.117:42467] helo=YT5PR01CU002.outbound.protection.outlook.com) by mx.cogeco.net (envelope-from ) (ecelerity 4.8.0.74062 r(msys-ecelerity:tags/4.8.0-ga^0)) with ESMTPS (cipher=TLS_AES_256_GCM_SHA384 subject="/C=US/ST=Washington/L=Redmond/O=Microsoft Corporation/CN=mail.protection.outlook.com") id 37/40-13295-2750F296; Tue, 02 Dec 2025 10:27:50 -0500 ARC-Seal: i=1; a=rsa-sha256; s=arcselector10001; d=microsoft.com; cv=none; b=Qu7SODM/dwDmhhZqnCMGE09Y9X1My1PsBjYebKtiXjKnnEgWqYmNY1z6SYYpUUvmTaHzDoRW9+5vpMdkOy9f/YcisoZ0be4Ltnaz3pzaITVIa/nVpXDp8LUpP5fzHiSrsvOdLcbTFmmYgwXwheoXy9EqrDJggciB7CjuMhNyZ2ih9JmhWppaJDZGVDjU4BA5kqgNhdzV0j3NeVXpkK3xtdyWJn2OwPP3Z11rzF2v0/MEnW1joTidGVrNeKDipU/ovL/aY1Wjdv9ApBvYOVRcJA2vRmo797D6EDb3uF9mGBfxmT+hCbzIz2Ltnpu5gi2i/Ya3iI5WAoFPcqFb0A8i+g== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=microsoft.com; s=arcselector10001; h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-AntiSpam-MessageData-ChunkCount:X-MS-Exchange-AntiSpam-MessageData-0:X-MS-Exchange-AntiSpam-MessageData-1; bh=tvn4daMT8VXUkvuLK3rXdSnuTaYqoIXfO2TW+qV71bk=; b=Ux48qadiyZmBJSYZb6Z4em/jKhlKVJrxDo3coRNgroTisMpmulyZKTBr17+HwNWZDIBwmy89XVZ+Yv2P1fwW2xk4/wZEuxrsxuoCv5XeftEpHxQgstPn5XD8yn3WOe/VNMevKTPEkFzHPT84lgx+hOCrNwQC8RYmCFkVxwARBaGrQAbexelkeAlcckHRQFb7Rqz/MmwRGmX5SP6hTojcYUKTfHiy+YdAn8PWQyijQdWmFNztPPxpmgurXT2c7sWep3OIXRKvdGIE6hSn05I3u2YFHdfGO6RQ9ASoO4Tq198hlZX7jree0EHBtZZRg34DKbwbkJb6AjH5HpTuXFqTTA== ARC-Authentication-Results: i=1; mx.microsoft.com 1; spf=pass smtp.mailfrom=prolab84.syenurelle.uk; dmarc=pass action=none header.from=prolab84.syenurelle.uk; dkim=pass header.d=prolab84.syenurelle.uk; arc=none Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=prolab84.syenurelle.uk; Date: Sat, 21 Feb 2026 17:02:38 +0100 Subject: The "High Payout" Angle (Greed/Benefit). From: 'Clinical Trial Alerts' To: "webmaster@globalnetworking.net" Auto-Submitted: auto-generated X-IncomingHeaderCount: 13 X-EOPAttributedMessage: 0 X-EOPTenantAttributedMessage: 84df9e7f-e9f6-40af-b435-aaaaaaaaaaaa:0 X-MS-TrafficTypeDiagnostic: DS2PEPF00003441:EE_|PAVPR02MB9354:EE_|AS8PR02MB9960:EE_|YQBPR0101MB9838:EE_|YT3PR01MB8625:EE_ X-MS-UserLastLogonTime: Tue, 02 Dec 2025 16:25:44 +0100 X-MS-Office365-Filtering-Correlation-Id: 94c906ac-1c50-4637-0f16-08de31b753fb X-MS-Exchange-EOPDirect: true X-Sender-IP: 46.30.212.211 X-SID-PRA: SALES@FR.ONE.COM X-SID-Result: PASS X-Microsoft-Antispam: BCL:0;ARA:13230040|14060799003|366016|376014|69100299015|52116014|1800799024|1032899013|35042699022|8096899003|3613699012|2066899003|38350700014|4076899003; X-MS-Exchange-CrossTenant-OriginalArrivalTime: Tue, 02 Dec 2025 16:25:44 +0100 (UTC) =?utf-8?Q?F0wmmI3i+eQwNM1RMBTOmi81iTo99pz4e0Y=3D?= Content-Transfer-Encoding: binary Content-Type: text/html; charset=UTF-8 X-Send-Method: smtp X-Hostname: mail.mta7145.ogwkyzzdz.org X-ClientProxiedBy: SA0PR11CA0101.namprd11.prod.outlook.com (2603:10b6:806:d1::16) To YQBPR0101MB9838.CANPRD01.PROD.OUTLOOK.COM (2603:10b6:c01:7a::17) MIME-Version: 1.0 X-MS-PublicTrafficType: Email X-MS-Office365-Filtering-Correlation-Id-Prvs: 5b7fcbc5-b955-423a-80b0-08dce9114030 X-MS-Exchange-SenderADCheck: 1 X-MS-Exchange-AntiSpam-Relay: 0 X-Microsoft-Antispam-Message-Info: =?utf-8?B?OHQ5anVPQWFMZHRsWE43T0Q4YjRSS1Q5bi9UTWFiYzdnWnFLSDZHcytaZGFw?= =?utf-8?B?bE51c0Y4dktIU24vQkVzUHRHQVYzZkFRNVhkbS9udTZaa2piL25sQXVkdnVL?= =?utf-8?B?ZE56ZzUzcjcxTnBOcGY3UURuU0tKM3hKdVRxTVV3NFFBS3gwLzBWRHF4Rjc5?= =?utf-8?B?VUdCeXFpQk91WFRITUFLZEloWmhManpXQU1WQVE3dTVGcmJ2SEJ0WWpIRGJq?= =?utf-8?B?UmMwNWswbngzdHZxbVRoeE9NVGtxMGE2V044c3FHV25PeEdYNVBrMlFoNFhq?= =?utf-8?B?YWp0c0pzNWREdXQ2UERKdHdkSVYxUi9CRm43d1RwTjhTSEtFTTVXOFhLRGFi?= =?utf-8?B?eTRwWDV4dW84U0IxOC9Kemc5cVBqcXhJUWNmRmFxWG92RXlHMmZVUlZPUE53?= =?utf-8?B?S0V3OFpiT0tydVhTVXQrNHRDbGN0QUdzb2gwSnBNc1JLcHhGOW9LQ1hSczda?= =?utf-8?B?QVBYV1NtaDY0V00rMGJrYWJ0MUV6bUNYYm9QVmNTSEUvV1FWRDNPQkp4MGlV?= =?utf-8?B?bWJpMWd6blZibEwwTkE4aFl0UXExYzBUTENOOVNwSWE5cEpnL0NhbUtOK0Fz?= =?utf-8?B?bHJtM0FFRHhYWGZ0QzBjQ0tUcksxMTZMd3p4MENwdHphanpQZUFDMW5GYnhl?= =?utf-8?B?NDIxb2FhUk8wallmMWlKTTJublZIWlk0OGhWRVRya05ORmF5L3JibllWSHp2?= =?utf-8?B?TWl5ampYM3M3dExIS2V0U2tHOVdzN29KK0NtZ0gvQmFMYktaQmxWbWdUSUh0?= =?utf-8?B?WlUzeDY2Y005cEdSdUc4dkJBMGJaNVduK1ZlejlzYVNORnpZWElqUjFsSnBF?= =?utf-8?B?ZTFaOXpyMkFPbENNM05kakdPdGJBbll5RUgxZzV5UEx6VGlEd2VEM01ueUVW?= =?utf-8?B?OWNNcnBhZmIybWQwaldUUXhKbEtPZVI1dSt0U0txVmVwYzFHUk1MbWpRV2dT?= =?utf-8?B?WkNlTW9iK0Uvc2JsdmVXS1BpTmlWVVRJYXFOTVAxK3A5MCs4NGhwZmVnd3Z5?= =?utf-8?B?UGtGVnN4YjUrYkFzeTlOWkFJdG1SNmQ4S3JLUVlTL0x6NVMrbmdHSDQ2bXNx?= =?utf-8?B?Q2FsU2hGQjJpenlqUldtdFhUMms2SmZBU2tZL1VuaVE1ajQ4b3d5R0JRRUtu?= =?utf-8?B?VEtiYlV2NWlXSmV3NzlzYVdnZnFOYTQ1blBHNFdUZklSMGdvbHRBcjZLMDVv?= =?utf-8?B?ak1VUGdRanowdTNveExiSS9IaHNqK3E5RHFyL0pGZXM1aUdyaFV2RmhpNktz?= =?utf-8?B?by83eEVXZndkMHkwVWZmWW5KeCtNb1ZZMkN6d28vQ253RzJYdVRKNFdsVzV2?= =?utf-8?B?ZFdLUGpKSnBkaUNMMmhVVWZzaEZDb3NLRFdxR3h0Njg2aExFMTZjZEs5NWg5?= =?utf-8?B?L3BZMzZhdTkrVXVUOHhMSU1qNHNBanltWm83RlZPeUQzdUM2VHg5SGhZVDZr?= =?utf-8?B?SWN5MmFxMS95cWE2NDdBUE5ZVlM3c250azd4MGtoMXlZTFUzcmdQT1RwZG5s?= =?utf-8?B?UHZqaE9sMVNLVnJBK0kxU2dBMDJuZ2lCMUlDdzlKL2JsZWtYVnpBc29md1li?= =?utf-8?B?Vjg0L3c3S1NZVHA1Qi83SGkyeDExdkl5ZW9OeTFmN0dOclMweUhNeFJWVzRt?= =?utf-8?B?VG13aWoxaHNBbjJYeDlQWG1tdGlwTGc9PQ==?= X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:YQBPR0101MB9838.CANPRD01.PROD.OUTLOOK.COM;PTR:;CAT:NONE;SFS:(13230040)(14060799003)(366016)(376014)(69100299015)(52116014)(1800799024)(1032899013)(35042699022)(8096899003)(3613699012)(2066899003)(38350700014)(4076899003);DIR:OUT;SFP:1102; X-MS-Exchange-AntiSpam-MessageData-ChunkCount: 1 X-MS-Exchange-AntiSpam-MessageData-0: =?utf-8?B?SktkV01GZWQ0akNmeXpBUEgxR3lPMktSaU04SThkQktCdzhaUzN3TTlLMkNv?= =?utf-8?B?eUV1SWcvbC9za1k5dU1jdjJMVURDT2h1THg0bGUyN0h6b21PdElWWmp0clYv?= =?utf-8?B?RS9aS1EyV0F4WERmRklmbkdmZHpsN3pYRk9SZzd4RWtRSGQweC82UTFpMWVy?= =?utf-8?B?RGcrd2g5VUpVOGNZaWd1OWljODhTY0h0L3RLTUJvck1qOG5xbDhtZ3hhQVRC?= =?utf-8?B?V0dxdmxnRVV6SHE3dDdsU1Z3eEtoajd0NVZXaDRWYUdodml2c3V4UVl4UlNx?= =?utf-8?B?U0c4OUo5WUpoQ3pWMXoyZDVYK3NaSko5SXovR0laYjRpalZiYk9INk90WENV?= =?utf-8?B?aFpEQnhhdnJzV2w4cDBNd2IvSGg4SmtkQ3l2NzFwZEhoSmVzMFJudU5NS1FM?= =?utf-8?B?RXJUbkRoaDF5VFY0OWNpMlhTZVk1a0lkVVBSbVM0TWtDMndCTE4wZWJGWDZt?= =?utf-8?B?cVN5VkFyMHJkazV5ZlJNVjZ2S3pNQ1hiWkh0UXVlTXExOTRRUzZpWXlkUXl3?= =?utf-8?B?VGJVTkVkNDArYzdTYTFaVjZXUUJtWk5lNXpsTnl1VXdkWm5vUXBxcjdIWGNu?= =?utf-8?B?alE2cU9mTFlvanBIbE5qOGJrSlV3OXpSclkzN3Z3QmdUYWFGbHFRY2VSbFBO?= =?utf-8?B?cFFEbnJFamFxOGl3d212cDR1dk9paGhPdDhwNmdyK1pJWHFNMWNuSys0bHNK?= =?utf-8?B?VS9YeDZMemc5WGVpMlQ2dGxOaUpsaE9OQ0VSNnpEN3U2S3BXV29WQ04vaDQ4?= =?utf-8?B?elFMVzh5cjArQjc1aUNpWjF3V1AveUJpa3FqcVhGQmJRa29KL2RFV2RiYk1x?= =?utf-8?B?Rk8zaitaVXkyc0xQYVk1WkZsZ0thTXBWdzZwMXkvTWIvRWFFd2FYaEJwUktM?= =?utf-8?B?bTQ5MW9xTFljZGI0NmhxQ3ZZSDJ4V20rK0kxUCtJaGc4WnU4UTQ1L3FTZTBD?= =?utf-8?B?THJ0a2ZmOHF4cVlFSzFzQ0g4VCtuUDZyY2xOVk42eVk5OW5qa3AxVjNDN0Fi?= =?utf-8?B?NDdTSnVDUUpqdThxU3RxNFZmVzBjWUJaWnBSTWUydURLQ0JmRU05V1lXbnZu?= =?utf-8?B?Z0t6VUhQbURSL1FjUWxzZEI5NEhBdzNRcCtUM1RZWUl5ZnhkUWFDNmFTS0pX?= =?utf-8?B?T2cyNXhjLzdiRE5vaEhIUGFDVTRKNWN3YWRwNDM4d0o2VjU4L21LSHkvakcr?= =?utf-8?B?SDFPNzJWZHZVcVIrb1YrMVVySFZ3UjFxWUozMElMQmVDR3FCbENGdThHYVhH?= =?utf-8?B?SVQwd0lkQzJZcC9ET0dSczhKUFhIb25BU1FqTnVydG16RWZvWGdEV2RDRzlu?= =?utf-8?B?dUtBYmxGeHRwQmh6MklZQzVvWTZBWFdnWHU2OCtJZWtxK0htdFlKTU9mTlE4?= =?utf-8?B?ZGphNG90cFRMbnNRWkVhOHNUZkYyWnZXa0s2aGtBMjVwNWJ5bUlNUk9PWUdD?= =?utf-8?B?VnZDRXBxMGhVOS9XU1NlWWorUVM0b01kclAvZ2ZRYnVWcWdYMkpMc0NPL29E?= =?utf-8?B?RXV0NjIvMjZHbDZ2NGtjNER4Q2thd0VDeEx0aFpaMFIrblI2YTFuN1lBVEJl?= =?utf-8?B?aWI0RFRGRVZYdklKUENzVG1jL1l3eXlGT20wWTA4MEZldEFlRW9YeW5jMERD?= =?utf-8?B?c0dKK0wvaXB4SlRMeGt2RGZDOGw4eVh2a1plSkhFNVdVLzQva2s5UjNmdUFJ?= =?utf-8?B?WXZYZkVHa2lBYi9rYytPWEp6QjVWb1Y2RGtXYzJCYVJDQjF6MmsxQ2kveGRB?= =?utf-8?B?UlRyUTQ2cVNBOXlXNVRwUm1UZVhxOGtONXVIblg4eVNMZmt4T0haSWJEajRV?= =?utf-8?B?M3hOaW9NUjB0NGJRS1RBYS93a05OK2xuT09vYXpkQVJ4SHo5UWU2S096c2ZM?= =?utf-8?B?SUoyVmZDaW5TWUt6Yi9xQ1VPTDNEa1NQR0ZqSm5YTm16NFUvUHF3cm5lTlNG?= =?utf-8?B?eEttRDk1U0wrS0hNZkhVdXN5NWEvcVFwNC9kYTc4akg5cE8zUG1GNThaNjRt?= =?utf-8?B?WUd1T3JWRmlDTkh4KzVKd0ZIMGs0dXhDNG5JM3NzNXFWeGNZY2pIR1hKVzgw?= =?utf-8?B?S1NKYy9GOUpNL2RRSDdqajNTWGNYQVRsdS9qamdTRDE1dVJDdjhhcWFZUFFZ?= =?utf-8?Q?pWRc=3D?= X-OriginatorOrg: prolab84.syenurelle.uk X-MS-Exchange-CrossTenant-Network-Message-Id: 94c906ac-1c50-4637-0f16-08de31b753fb X-MS-Exchange-CrossTenant-AuthSource: YQBPR0101MB9838.CANPRD01.PROD.OUTLOOK.COM X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-OriginalArrivalTime: 02 Dec 2025 15:27:39.2729 (UTC) X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-CrossTenant-Id: 83934313-fcdc-41ad-b704-1576d1bd2705 X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: +FJNaAKvv/ES6JVmTMiYtAsiyZnbQLiPUpIq31H8RO/HaKo0cDAxRiIneIegKp39sgYkDFHd4U+3Jn31o7zGoe40fkqXBu4+q12+ukiuVELVsWs4TVEtuN4Cy1Nk4HQJ X-MS-Exchange-Transport-CrossTenantHeadersStamped: YT3PR01MB8625 X-Vade-Verdict: clean X-Vade-Analysis-1: dmFkZTFB2BdE4qM6kYzzIdJNe8XRtXTUosvquyWzJ9WtC0/MRlP7g0cHaZCMvq0fHfvn00UrgtoXVWkk X-Vade-Analysis-2: SN9okNRmzGAp9nhlfsEOlNsdqaWhKQIpqkiflp9auz4KUuYWA1Z4dbd10IApY+ZOr55Uj5WT9zhD0cyL X-Vade-Analysis-3: SigQWuUH22EJuDlOIV83PQbO5mmJvYJrPo+iTCb+H4PHtjxaguliYfgKOHITb9fzp5EZSbZNC28vj5T4 X-Vade-Analysis-4: rGyrTaraiLePFNd3ZYnpPlL1TvkSBOacGjbVAHPsjpI1IxoHYxKZElZ8IuN8aXOHaGwaL89jJ89n7ugK X-Vade-Analysis-5: 9MD97TPMNh3tapKQIw2N2f/ON0eTOFk5LVpAoNY1291pRDNu8H2hmQq7azWP/wJEQrgXNAG51um2vuZC X-Vade-Analysis-6: abLCjbF6qJ84cTtgGj3g9vawBRiq1PUcyrzA2SioBn0WyUwGs1Iu5eDSrszF+RNiEmWFRHHfTtHALJ4a X-Vade-Analysis-7: eFdBNG5oDTH2wMnb3RR2nuIINkitMgvfsuDhneDYChGq8bU8cU/MginSA1jUcFgaOMW8T/Qt9jBXoDtv X-Vade-Analysis-8: aNeEkQEiiCeVtouQxaGcsTXnS8J9kTElhV3TRAkNIAe/gkl1muFsxSwNgay/UaR9mhV+8K4w5D+e1A6c X-Vade-Analysis-9: fXqezc3u9daBiGFwjkq5/PX4+XePmjZn6ni8K4x2pSKCxKXsGw Trial Eligibility
Check your eligibility for paid research studies near you. Pay range: $300 - $3,000.

Hi,

Local research organizations are currently seeking participants for upcoming clinical trials.

We noticed you are in a qualifying area. Depending on the study, participants are earning between $300 and $3,000+ for their time.

It takes less than 60 seconds to check if you qualify:

Check Eligibility Here ยป

Study Details:

  • Available for all experience levels.
  • Open to healthy volunteers and those with conditions.
  • Free and confidential.

Please answer the housing question on the next page to route your application correctly.

Best regards,
The Research Team



You received this email because you subscribed to our notification list.
Unsubscribe here if you no longer wish to receive alerts.



click here to remove yourself from our emails list